Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.38 Analyst target: $95.40 Upside: 819.08%
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.